Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP668412.RAaoInMm2hYO7jcRbwYMao4H1FHuqWCoCx31rJ6yHNnJc130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP668412.RAaoInMm2hYO7jcRbwYMao4H1FHuqWCoCx31rJ6yHNnJc130_provenance.
• assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP325521.RAhth3rWMgTO1Os-aIps8nkgfa40q_aKXA292C9X8-pMA130_provenance.
• NP927608.RAo8Nig4fFdHo8w08EEGzg1McYB8NJuXR3zZhoXH2x3j0130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP927608.RAo8Nig4fFdHo8w08EEGzg1McYB8NJuXR3zZhoXH2x3j0130_provenance.
• assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1081788.RAaZj5tSiveyWJk8bel2_bwhMhSvewGrSLxuBkG37cZNQ130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081788.RAaZj5tSiveyWJk8bel2_bwhMhSvewGrSLxuBkG37cZNQ130_provenance.
• NP1081789.RAcwh7vKw8C90eKdN7OiDJoZKg48vampSsucbTQ6Bkoy8130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081789.RAcwh7vKw8C90eKdN7OiDJoZKg48vampSsucbTQ6Bkoy8130_provenance.
• NP371925.RAgFF7t3JW0_bZTrNZOVMrvBlJxfgNfbNJL1oKz_n-rao130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP371925.RAgFF7t3JW0_bZTrNZOVMrvBlJxfgNfbNJL1oKz_n-rao130_provenance.
• NP372170.RAgbdvB_nneYrkrx_edqsj8mm43prhURCdD8A73kPj8RM130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP372170.RAgbdvB_nneYrkrx_edqsj8mm43prhURCdD8A73kPj8RM130_provenance.
• NP668290.RAkl6Ks6HZqtOlJIWkXIETATHADYXR_3NlYMqwgocdBKU130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP668290.RAkl6Ks6HZqtOlJIWkXIETATHADYXR_3NlYMqwgocdBKU130_provenance.
• NP1081796.RAmMUB6WO6QU_RdqDlYfyt79sa0cQpPBgbgpXsz1OA-4g130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081796.RAmMUB6WO6QU_RdqDlYfyt79sa0cQpPBgbgpXsz1OA-4g130_provenance.
• NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_provenance.
• NP325740.RA3mKFt3fStWAvZvtXAXF8YWtj-61TghsEi3esVasgrbw130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP325740.RA3mKFt3fStWAvZvtXAXF8YWtj-61TghsEi3esVasgrbw130_provenance.
• NP927725.RAJxjo5I7ol5V6S22DWM10936ZV1pdpDwDRI_vdYBxYIA130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP927725.RAJxjo5I7ol5V6S22DWM10936ZV1pdpDwDRI_vdYBxYIA130_provenance.
• NP921184.RAMJHAD44cE97sxJ4D4gGAxdAnLq_houu9OH2xyoPgagU130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP921184.RAMJHAD44cE97sxJ4D4gGAxdAnLq_houu9OH2xyoPgagU130_provenance.
• NP1081804.RAObn8AETKNs2RtQrQs-SsGynXJEk5RTzD0gOtaDJJ3W0130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081804.RAObn8AETKNs2RtQrQs-SsGynXJEk5RTzD0gOtaDJJ3W0130_provenance.
• NP1081786.RA24T0VratpTMoZwbu5v0jehJyKAgCNmqiB_yPDsNm6Vk130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081786.RA24T0VratpTMoZwbu5v0jehJyKAgCNmqiB_yPDsNm6Vk130_provenance.
• NP1081791.RA2NtIrx_jb6itCFKv-MCjmsmxTqjnuREaJJ5wXi4x-BM130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081791.RA2NtIrx_jb6itCFKv-MCjmsmxTqjnuREaJJ5wXi4x-BM130_provenance.
• NP1081795.RA43ZNFWplbfJBJcnYawd31s5sXQxprX2IzmoF-MAg6o4130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081795.RA43ZNFWplbfJBJcnYawd31s5sXQxprX2IzmoF-MAg6o4130_provenance.
• NP1081797.RAyskdvf61WYlpPDC5UiN6AgkkdY84gkYgCerWcf-VY2I130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081797.RAyskdvf61WYlpPDC5UiN6AgkkdY84gkYgCerWcf-VY2I130_provenance.
• NP1081798.RA5BdpzmHkShMfMhxwK6Uhqn6jQACA1wU0uA3_mw_9oGg130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081798.RA5BdpzmHkShMfMhxwK6Uhqn6jQACA1wU0uA3_mw_9oGg130_provenance.
• NP1081800.RA2Ujws-ngGkBhiNAf9OF3c8bA8AaRVlfDNLYoyPizldY130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081800.RA2Ujws-ngGkBhiNAf9OF3c8bA8AaRVlfDNLYoyPizldY130_provenance.
• NP1081802.RAzmliypvycWRqssoJ5E-T2D4tXST7x4SCvRsmVorAYTM130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081802.RAzmliypvycWRqssoJ5E-T2D4tXST7x4SCvRsmVorAYTM130_provenance.
• NP921309.RA_GJxcuUa-GLmUd9CefxDsHhX9Vh2GnYbdBbIzJ-0huc130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP921309.RA_GJxcuUa-GLmUd9CefxDsHhX9Vh2GnYbdBbIzJ-0huc130_provenance.